期刊
MARINE LIFE SCIENCE & TECHNOLOGY
卷 4, 期 2, 页码 245-254出版社
SPRINGERNATURE
DOI: 10.1007/s42995-022-00127-0
关键词
Sulfated rhamnose polysaccharides; Enteromorpha prolifera; Chromium; Hypolipidemic; Type 2 diabetic mice
资金
- Innovation Capability Improvement Project of Shandong [2021TSGC1298]
- Qingdao Science and Technology Project [2022]
SRPE-3-Cr(III), a variant of sulfated rhamnose polysaccharide derived from Enteromorpha prolifera, has shown potential as a novel compound to treat diabetes. The study demonstrated that SRPE-3-Cr(III) has hypolipidemic effects and improves lipid metabolism in type 2 diabetes induced by a high-fat, high-sucrose diet. It also regulates adipokines and inflammatory factors, and alleviates tissue damage caused by the diet.
Sulfated rhamnose polysaccharide (SRP) derived from Enteromorpha prolifera is a metal-ion chelating agent that could potentially be used to treat diabetes. The aim of our study was to determine the effect of a variant of SRP on DIABETES. First, we synthesized and characterized SRPE-3 chromium(III) [SRPE-3-Cr(III)] complex using an enzymatic method. The maximum chelation rate was 18.2% under optimal chelating conditions of pH 6.0, time 4 h, and temperature 60 degrees C. Fourier transform infrared spectroscopy results showed important sites for Cr(III)-binding were O-H and C=O groups. We then studied the hypolipidemic effects of SRPE-3-Cr(III) on type 2 diabetes mellitus (T2DM) induced by a high-fat, high-sucrose diet (HFSD). Decreased blood glucose content, body fat ratio, serum TG, TC, LDL-C, and increased serum HDL-C were observed after treatment with SRPE-3-Cr(III). In addition, SRPE-3-Cr(III) significantly reduced leptin, resistin, and TNF-alpha levels, and increased adiponectin contents relative to T2DM. Histopathology results also showed that SRPE-3-Cr(III) could alleviate the HFSD-lesioned tissues. SRPE-3-Cr(III) also improved lipid metabolism via a reduction in aspartate aminotransferase, alanine aminotransferase, fatty acid synthase, and acetyl-CoA carboxylase activities in the liver. SRPE-3-Cr(III) at low doses exhibited better lipid-lowering activities, hence, could be considered to be a novel compound to treat hyperlipidemia and also act as an anti-diabetic agent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据